Pharmaceutical Drug Delivery Market By Route of Administration, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Pharmaceutical Drug Delivery Market," The pharmaceutical drug delivery market was valued at $1,498.72 billion in 2022, and is estimated to reach $2307.27 billion by 2032, growing at a CAGR of 4.4% from 2023 to 2032.

Pharmaceutical Drug Delivery Market - IMG1

Chronic diseases, such as cardiovascular disorders, diabetes, cancer, and respiratory diseases, are characterized by long-term medication treatment. These conditions require regular administration of drugs to control symptoms, slow disease progression, or maintain quality of life. This has increased the demand for effective drug delivery systems, thereby driving the market growth. According to International Diabetes Federation (IDF), in 2021, it was estimated that about 3 in 4 adults with diabetes live in low and middle-income countries and approximately 206 million people were diagnosed with diabetes in western pacific.

For instance, in May 2022, U.S. Food and Drug Administration (FDA), approved new injectable delivery product, Mounjaro to treat type 2 diabetes. Thus, the rise in prevalence of diabetes has led to the development of advanced insulin delivery systems, which are highly effective to treat diabetes. In addition, growth in prevalence of age-related diseases such as cardiovascular disorders, arthritis, neurodegenerative diseases, and osteoporosis have created a significant demand for effective drug delivery.

For instance, in January 2023, Biogen Inc., one of the global leader in pharmaceutical industry, received U.S. Food and Drug Administration (FDA) approval for LEQEMBI to treat Alzheimer's disease. LEQEMBI is a monoclonal antibody directed intravenous drug delivery medication that effectively treats Alzheimer's disease. Thus, development of new targeted drug delivery and controlled release formulation further contribute toward the market growth. However, stringent regulatory requirements can increase the time, cost, and complexity of new drug delivery technologies and restrain market growth. Furthermore, high costs associated with research and development of new drug delivery negatively impact market growth.

On the other hand, an increase in demand for advanced drug delivery systems is expected to create lucrative opportunities for market growth during the forecast period. This is attributed to the increase in prevalence of chronic diseases, enhanced treatment outcomes, and availability of favorable reimbursement policies for the development of advanced drug delivery systems.

The pharmaceutical drug delivery market is segmented on the basis of route of administration, application, and region. On the basis of route of administration, the market is classified into oral drug delivery, nasal drug delivery, ocular drug delivery, topical drug delivery, and other drug delivery. As per application, the market is categorized into cancer, diabetes, cardiovascular diseases, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global pharmaceutical drug delivery market are: Bayer AG, Cipla Ltd, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Amgen Inc., Pfizer Inc., Sanofi. Key players operating in the market have adopted product launch and product approval as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical drug delivery market analysis from 2022 to 2032 to identify the prevailing pharmaceutical drug delivery market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the pharmaceutical drug delivery market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global pharmaceutical drug delivery market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Route of Administration

Topical drug delivery
Other drug delivery
Oral drug delivery
Nasal drug delivery
Ocular drug delivery

By Application

Cancer
Diabetes
Cardiovascular Diseases
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Amgen Inc.
Bayer AG
Cipla Ltd
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.

Product Code: A06102

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of various chronic diseases
  - 3.4.1.2. Technological advancement in drug delivery systems

3.4.2. Restraints
- 3.4.2.1. Stringent regulatory requirements for the approval of pharmaceutical drug delivery

3.4.3. Opportunities
- 3.4.3.1. Increase in demand for advanced delivery systems

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Oral drug delivery
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Nasal drug delivery
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Ocular drug delivery
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Topical drug delivery
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Other drug delivery
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country

CHAPTER 5: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Cancer
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Diabetes
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Cardiovascular Diseases
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Others
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country

CHAPTER 6: PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION

6.1. Overview
- 6.1.1. Market size and forecast By Region
6.2. North America
- 6.2.1. Key trends and opportunities
- 6.2.2. Market size and forecast, by Route of Administration
- 6.2.3. Market size and forecast, by Application
- 6.2.4. Market size and forecast, by country
  - 6.2.4.1. U.S.
  - 6.2.4.1.1. Key market trends, growth factors and opportunities
  - 6.2.4.1.2. Market size and forecast, by Route of Administration
  - 6.2.4.1.3. Market size and forecast, by Application
  - 6.2.4.2. Canada
  - 6.2.4.2.1. Key market trends, growth factors and opportunities
  - 6.2.4.2.2. Market size and forecast, by Route of Administration
  - 6.2.4.2.3. Market size and forecast, by Application
  - 6.2.4.3. Mexico
  - 6.2.4.3.1. Key market trends, growth factors and opportunities
  - 6.2.4.3.2. Market size and forecast, by Route of Administration
  - 6.2.4.3.3. Market size and forecast, by Application
6.3. Europe
- 6.3.1. Key trends and opportunities
- 6.3.2. Market size and forecast, by Route of Administration
- 6.3.3. Market size and forecast, by Application
- 6.3.4. Market size and forecast, by country
  - 6.3.4.1. Germany
  - 6.3.4.1.1. Key market trends, growth factors and opportunities
  - 6.3.4.1.2. Market size and forecast, by Route of Administration
  - 6.3.4.1.3. Market size and forecast, by Application
  - 6.3.4.2. France
  - 6.3.4.2.1. Key market trends, growth factors and opportunities
  - 6.3.4.2.2. Market size and forecast, by Route of Administration
  - 6.3.4.2.3. Market size and forecast, by Application
  - 6.3.4.3. UK
  - 6.3.4.3.1. Key market trends, growth factors and opportunities
  - 6.3.4.3.2. Market size and forecast, by Route of Administration
  - 6.3.4.3.3. Market size and forecast, by Application
  - 6.3.4.4. Italy
  - 6.3.4.4.1. Key market trends, growth factors and opportunities
  - 6.3.4.4.2. Market size and forecast, by Route of Administration
  - 6.3.4.4.3. Market size and forecast, by Application
  - 6.3.4.5. Spain
  - 6.3.4.5.1. Key market trends, growth factors and opportunities
  - 6.3.4.5.2. Market size and forecast, by Route of Administration
  - 6.3.4.5.3. Market size and forecast, by Application
  - 6.3.4.6. Rest of Europe
  - 6.3.4.6.1. Key market trends, growth factors and opportunities
  - 6.3.4.6.2. Market size and forecast, by Route of Administration
  - 6.3.4.6.3. Market size and forecast, by Application
6.4. Asia-Pacific
- 6.4.1. Key trends and opportunities
- 6.4.2. Market size and forecast, by Route of Administration
- 6.4.3. Market size and forecast, by Application
- 6.4.4. Market size and forecast, by country
  - 6.4.4.1. Japan
  - 6.4.4.1.1. Key market trends, growth factors and opportunities
  - 6.4.4.1.2. Market size and forecast, by Route of Administration
  - 6.4.4.1.3. Market size and forecast, by Application
  - 6.4.4.2. China
  - 6.4.4.2.1. Key market trends, growth factors and opportunities
  - 6.4.4.2.2. Market size and forecast, by Route of Administration
  - 6.4.4.2.3. Market size and forecast, by Application
  - 6.4.4.3. India
  - 6.4.4.3.1. Key market trends, growth factors and opportunities
  - 6.4.4.3.2. Market size and forecast, by Route of Administration
  - 6.4.4.3.3. Market size and forecast, by Application
  - 6.4.4.4. Australia
  - 6.4.4.4.1. Key market trends, growth factors and opportunities
  - 6.4.4.4.2. Market size and forecast, by Route of Administration
  - 6.4.4.4.3. Market size and forecast, by Application
  - 6.4.4.5. South Korea
  - 6.4.4.5.1. Key market trends, growth factors and opportunities
  - 6.4.4.5.2. Market size and forecast, by Route of Administration
  - 6.4.4.5.3. Market size and forecast, by Application
  - 6.4.4.6. Rest of Asia-Pacific
  - 6.4.4.6.1. Key market trends, growth factors and opportunities
  - 6.4.4.6.2. Market size and forecast, by Route of Administration
  - 6.4.4.6.3. Market size and forecast, by Application
6.5. LAMEA
- 6.5.1. Key trends and opportunities
- 6.5.2. Market size and forecast, by Route of Administration
- 6.5.3. Market size and forecast, by Application
- 6.5.4. Market size and forecast, by country
  - 6.5.4.1. Brazil
  - 6.5.4.1.1. Key market trends, growth factors and opportunities
  - 6.5.4.1.2. Market size and forecast, by Route of Administration
  - 6.5.4.1.3. Market size and forecast, by Application
  - 6.5.4.2. Saudi Arabia
  - 6.5.4.2.1. Key market trends, growth factors and opportunities
  - 6.5.4.2.2. Market size and forecast, by Route of Administration
  - 6.5.4.2.3. Market size and forecast, by Application
  - 6.5.4.3. South Africa
  - 6.5.4.3.1. Key market trends, growth factors and opportunities
  - 6.5.4.3.2. Market size and forecast, by Route of Administration
  - 6.5.4.3.3. Market size and forecast, by Application
  - 6.5.4.4. Rest of LAMEA
  - 6.5.4.4.1. Key market trends, growth factors and opportunities
  - 6.5.4.4.2. Market size and forecast, by Route of Administration
  - 6.5.4.4.3. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. F. Hoffmann-La Roche Ltd.
- 8.1.1. Company overview
- 8.1.2. Key Executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
8.2. GlaxoSmithKline plc
- 8.2.1. Company overview
- 8.2.2. Key Executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
8.3. Johnson & Johnson
- 8.3.1. Company overview
- 8.3.2. Key Executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
8.4. Merck & Co., Inc.
- 8.4.1. Company overview
- 8.4.2. Key Executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
8.5. Novartis AG
- 8.5.1. Company overview
- 8.5.2. Key Executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
- 8.5.7. Key strategic moves and developments
8.6. Pfizer Inc.
- 8.6.1. Company overview
- 8.6.2. Key Executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
8.7. Sanofi S.A.
- 8.7.1. Company overview
- 8.7.2. Key Executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
8.8. Bayer AG
- 8.8.1. Company overview
- 8.8.2. Key Executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
8.9. Cipla Ltd
- 8.9.1. Company overview
- 8.9.2. Key Executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
8.10. Amgen Inc.
- 8.10.1. Company overview
- 8.10.2. Key Executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Business performance